Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

Melanoma May Be Triggered by Deficit of Retinoid-X-Receptors in Melanocytes

By BiotechDaily International staff writers
Posted on 20 May 2014
Image: Arup and Gitali Indra are beginning to find clues to predicting, preventing and stopping melanoma before it spreads (Photo courtesy of Karl Maasdam / Oregon State University College of Pharmacy).
Image: Arup and Gitali Indra are beginning to find clues to predicting, preventing and stopping melanoma before it spreads (Photo courtesy of Karl Maasdam / Oregon State University College of Pharmacy).
Cancer researchers have linked the development of the deadly skin cancer melanoma to depressed expression in melanocytes of the type II nuclear receptors Retinoid-X-Receptor alpha (RXRalpha) and Retinoid-X-Receptor beta (RXRbeta).

Melanoma is the deadliest form of skin cancer. It derives from melanocytes, the melanin-producing cells of the skin, which give the skin its tone in addition to protecting it from harmful effects of ultraviolet radiation (UVR). Changes in the skin microenvironment, such as signaling from other cell types, can influence melanoma progression. While several key genes in melanoma development have been identified, the underlying mechanisms are complex; different combinations of mutations can result in melanoma formation and genetic profiles of tumors can vary greatly among patients.

Retinoid X receptors (RXRs) are nuclear receptors that mediate the biological effects of retinoids (vitamin A derivatives) by their involvement in retinoic acid-mediated gene activation. These receptors function as transcription factors by binding as homodimers or heterodimers to specific sequences in the promoters of target genes. The protein encoded by this gene is a member of the steroid and thyroid hormone receptor superfamily of transcriptional regulators.

Since expression of RXRalpha disappears during melanoma progression in humans, investigators at Oregon State University (Corvallis, USA) developed a tissue-specific gene ablation strategy to characterize the role of these type II nuclear receptors in melanocytes to control UVR-induced skin immune responses and cell survival.

They reported in the May 8, 2014, online edition of the journal PLoS Genetics that melanocytes in mice with melanocyte-specific ablation of RXRalpha and RXRbeta attracted fewer IFN-gamma (interferon-gamma) secreting immune cells than in wild-type mice following acute UVR exposure, via altered expression of several chemoattractive and chemorepulsive chemokines/cytokines. Reduced IFN-gamma in the microenvironment altered UVR-induced apoptosis, and due to this, the survival of surrounding dermal fibroblasts was significantly decreased in mice lacking RXRalpha/beta.

These results emphasized a novel immunomodulatory role for melanocytes in controlling survival of neighboring cell types besides controlling their own, and identified RXRs as potential targets for therapy against UV induced melanoma.

"We believe this is a breakthrough in understanding exactly what leads to cancer formation in melanoma," said senior author Dr. Arup Indra, associate professor of pharmacology at Oregon State University. "We have found that some of the mechanisms which ordinarily prevent cancer are being switched around and actually help promote it. When there is not enough RXR, the melanocytes that exist to help shield against cancer ultimately become part of the problem. It is routine to have genetic damage from sunlight, because normally those cells can be repaired or killed if necessary. It is the breakdown of these control processes that result in cancer, and that happens when RXR levels get too low. It is quite possible that a new and effective therapy can now be developed, based on increasing levels of RXR."

Related Links:

Oregon State University



Channels

Drug Discovery

view channel

Curcumin Used to Treat Alzheimer’s Disease

Curcumin, a natural substance found in the spice turmeric, has been used by many Asian cultures for centuries. Now, new research suggests that a close chemical analog of curcumin has properties that may make it useful as a treatment for Alzheimer’s disease. “Curcumin has demonstrated ability to enter the brain, bind... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Therapeutics

view channel
Image: Cancer cells infected with tumor-targeted oncolytic virus (red). Green indicates alpha-tubulin, a cell skeleton protein. Blue is DNA in the cancer cell nuclei (Photo courtesy of Dr. Rathi Gangeswaran, Bart’s Cancer Institute).

Innovative “Viro-Immunotherapy” Designed to Kill Breast Cancer Cells

A leading scientist has devised a new treatment that employs viruses to kill breast cancer cells. The research could lead to a promising “viro-immunotherapy” for patients with triple-negative breast cancer,... Read more

Lab Technologies

view channel
Image: MIT researchers have designed a microfluidic device that allows them to precisely trap pairs of cells (one red, one green) and observe how they interact over time (Photo courtesy of Burak Dura, MIT).

New Device Designed to See Communication between Immune Cells

The immune system is a complicated network of many different cells working together to defend against invaders. Effectively combating an infection depends on the interactions between these cells.... Read more

Business

view channel

Program Designed to Provide High-Performance Computing Cluster Systems for Bioinformatics Research

Dedicated Computing (Waukesha, WI, USA), a global technology company, reported that it will be participating in the Intel Cluster Ready program to deliver integrated high-performance computing cluster solutions to the life sciences market. Powered by Intel Xeon processors, Dedicated Computing is providing a range of... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.